, Volume 15, Issue 2, pp 109–114 | Cite as

Treatment selection for esophageal cancer: evaluation from a nationwide database

  • Yasuo Hamamoto
  • Naoki Sakakibara
  • Fumio Nagashima
  • Yuko Kitagawa
  • Takahiro Higashi
Original Article



Most elderly patients poorly tolerate the standard treatment for esophageal cancer; however, little information is available regarding the appropriateness of non-standard esophageal cancer treatments for those patients. This study aims to analyze the treatment costs and completion rates of patients undergoing a real-world treatment for esophageal cancer to elucidate the treatment selection and its quality.

Materials and methods

We analyzed treatment costs and completion rates for patients with esophageal cancer and analyzed these data relative to patient age and center volumes. Patients with esophageal cancer [UICC, TMN, Clinical stage II/III (excluding T4)] who were diagnosed in 2013 were analyzed. Patients were classified into five groups defined as follows: surgical therapy, chemotherapy, concurrent chemoradiotherapy (CCRT), modified concurrent chemoradiotherapy (mCRT), and radiotherapy (RT).


Mean and median age of patients who received surgery and CCRT were comparable; however, patients who underwent mCRT and RT tended to be older. Medical costs associated with surgery were higher than costs associated with other non-surgical treatments. Cost and completion rate of chemoradiotherapy did not differ between CCRT and mCRT; however, both had higher completion rates compared to that of RT. Surgical expenses tended to be the highest in low-volume centers and the lowest in high-volume centers.


Treatment of esophageal cancer at high-volume centers seems well balanced compared with medium- to low-volume centers. mCRT was widely performed and comparable in medical cost to CCRT, although additional clinical impacts were unclear.


Esophageal cancer Chemoradiotherapy Elderly Costs of care Hospital-based cancer registries 



Diagnosis Procedure Combination


Concurrent chemoradiotherapy


Modified concurrent chemoradiotherapy




Designated Cancer Care Hospitals


Hospital-based cancer registries


Compliance with ethical standards

Ethical Statement

Authors declare that our work conforms to the guidelines set forth in the Helsinki Declaration of 1975, as revised in 2000, concerning Human and Animal Rights, and that they followed the policy concerning Informed Consent.

Conflict of interest

Naoki Sakakibara, Fumio Nagashima, and Takahiro Higashi have no conflicts of interest. Yasuo Hamamoto has conflicts of interest to declare with regard to this manuscript: Ono Pharmaceutical Co. Yuko Kitagawa has conflicts of interest to declare with regard to this manuscript: Ethicon, Ono Pharmaceutical Co., Taiho Pharma, Chugai Pharmaceutical co., Asahi Kasei Pharma, Otsuka Pharmaceutical Co., Kyowa Hakko Kirin Co., Daiichi Sankyo co., Takeda Pharmaceutical Co. Nippon Boehringer Ingelheim Co., Novartis Pharma., Pfeizer Japan, Merck Serono Co., Yakult Honsha co., Terumo Corporation, Torii Pharmaceutical Co., Astra Zeneca.


  1. 1.
    Rustgi A, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2015;372(15):1472–3.PubMedGoogle Scholar
  2. 2.
    Ajani JA, D’Amico TA, Almhanna K, et al. Esophageal and esophagogastric junction cancers, version 1.2015. National comprehensive cancer network. J Natl Compr Canc Netw. 2015;13(2):194–227.CrossRefPubMedGoogle Scholar
  3. 3.
    Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(5):v50–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Kuwano H, Nishimura Y, Oyama T. Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2012 edited by the Japan Esophageal Society. Esophagus. 2015;12:1–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Hamamoto Y, Akutsu Y, Nagashima F, et al. Multicenter questionnaire survey on patterns of care for elderly patients with esophageal squamous cell carcinoma by the Japan Esophageal Oncology Group. Jpn J Clin Oncol. 2016;46(2):111–5.PubMedGoogle Scholar
  6. 6.
    Takeuchi S, Ohtsu A, Doi T, et al. A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer. Am J Clin Oncol. 2007;30(6):607–11.CrossRefPubMedGoogle Scholar
  7. 7.
    Morita M, Egashira A, Yoshida R, et al. Esophagectomy in patients 80 years of age and older with carcinoma of the thoracic esophagus. J Gastroenterol. 2008;43(5):345–51.CrossRefPubMedGoogle Scholar
  8. 8.
    Tougeron D, Di Fiore F, Thureau S, et al. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer. 2008;99(10):1586–92.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Anderson SE, Minsky BD, Bains M, et al. Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer. 2007;96(12):1823–7.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Steyerberg EW, Earle CC, Neville BA, Weeks JC. Racial differences in surgical evaluation, treatment, and outcome of locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2005;23(3):510–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Steyerberg EW, Neville B, Weeks JC, Earle CC. Referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2007;25(17):2389–96.CrossRefPubMedGoogle Scholar
  12. 12.
    Smith GL, Smith BD, Buchholz TA, et al. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: the SEER-medicare cohort. Int J Radiat Oncol Biol Phys. 2009;74(2):482–9. Epub 2009 Mar.CrossRefPubMedGoogle Scholar
  13. 13.
    Higashi T, Nakamura F, Shibata A, et al. The national database of hospital-based cancer registries: a nationwide infrastructure to support evidence-based cancer care and cancer control policy in Japan. Jpn J Clin Oncol. 2014;44(1):2–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Iwamoto M, Nakamura F, Higashi T. Monitoring and evaluating the quality of cancer care in Japan using administrative claims data. Cancer Sci. 2016;107(1):68–75.CrossRefPubMedGoogle Scholar
  15. 15.
    NationalComprehensiveCancerNetwork. NCCN clinical practice guidelines in oncology esophageal and esophagogastric junction cancers: NCCN. org; Version 2. 2016.Google Scholar
  16. 16.
    Suntharalingam M, Moughan J, Coia LR. Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2325–31.CrossRefPubMedGoogle Scholar
  17. 17.
    Markar SR, Low DE. Physiology, not chronology, dictates outcomes after esophagectomy for esophageal cancer: outcomes in patients 80 years and older. Ann Surg Oncol. 2013;20(3):1020–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Atagi S, Kawahara M, Yokoyama A. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. 2012;13(7):671–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Tsukada Y, Nakamura F, Iwamoto M, et al. Are hospitals in Japan with larger patient volume treating younger and earlier-stage cancer patients? An analysis of hospital-based cancer registry data in Japan. Jpn J Clin Oncol. 2015;45(8):719–26.CrossRefPubMedGoogle Scholar
  20. 20.
    Kurokawa Y, Boku N, Yamaguchi T, et al. Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial. ESMO Open. 2016;1(1):e000031.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hamamoto Y, Mizusawa J, Katayama H, et al. Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study. Jpn J Clin Oncol. 2016;46(4):389–92.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hamamoto Y, Nojima M, Aoki Y, et al. Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma. Esophagus. 2017. Scholar
  23. 23.
    Corry J, Peters LJ, Rischin D. Impact of center size and experience on outcomes in head and neck cancer. J Clin Oncol. 2015;33(2):138–40.CrossRefPubMedGoogle Scholar
  24. 24.
    Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med. 2011;364(22):2128–37. Scholar

Copyright information

© The Japan Esophageal Society and Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Health Services Research, Center for Cancer Control and Information ServicesNational Cancer CenterTokyoJapan
  2. 2.Keio Cancer CenterKeio University School of MedicineTokyoJapan
  3. 3.Department of Medical OncologyKyorin University School of MedicineMitaka-shi, TokyoJapan
  4. 4.Department of SurgeryKeio University School of MedicineTokyoJapan

Personalised recommendations